Ch 71 NSAIDs and acetaminophen Flashcards
All of the drugs discussed in this chapter inhibit __.
cyclooxygenase (COX),
an enzyme that converts arachidonic acid into prostanoids (prostaglandins and related compounds).
Cyclooxygenase has two forms:
COX-1 and COX-2.
The cyclooxygenase inhibitors fall into two major groups:
nonsteroidal anti-inflammatory drugs (NSAIDs) and
acetaminophen (in a group by itself).
The NSAIDs can be subdivided into two groups:
(1) firstgeneration NSAIDs, which inhibit COX-1 and COX-2, and
(2) second-generation NSAIDs, which selectively inhibit COX-2.
Inhibition of COX-1 can cause (3).
gastric ulceration, renal impairment, and bleeding
Inhibition of COX-2 suppresses __.
inflammation, pain, and fever, but can also cause renal impairment
__ is the prototype of the first-generation NSAIDs.
Aspirin
Aspirin has four major beneficial actions:
suppression of inflammation,
relief of mild to moderate pain,
reduction of fever, and
prevention of MI and stroke (secondary to suppressing platelet aggregation).
All of these benefits result from inhibiting COX-2, except for prevention of MI and stroke, which results from inhibiting COX-1 (in platelets).
Because aspirin inhibits COX-1 as well as COX-2, it cannot cause beneficial effects without posing a risk of (3).
gastric ulceration, bleeding, and renal impairment.
__ causes irreversible inhibition of cyclooxygenase.
Aspirin
As a result, the effects of aspirin persist until cells can
make more cyclooxygenase.
Because platelets are unable to synthesize new cyclooxygenase, the antiplatelet effects of a single dose of aspirin __.
persist for the life of the platelet (about 8 days).
__ of aspirin are much higher than analgesic or antipyretic doses.
Anti-inflammatory doses
__ is a useful drug for rheumatoid arthritis and other chronic inflammatory conditions.
Aspirin
Aspirin is a very effective __.
analgesic.
It can be as effective as opioids for some types of postoperative pain.
The risk of aspirin-induced gastric ulcers can be reduced
by:
(1) testing for and eliminating H. pylori before starting
therapy and by
(2) giving a proton pump inhibitor or histamine2 receptor antagonist.